PCP
FDMT icon

Proficio Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Proficio Capital Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,121
Closed -$175K – 251
2025
Q3 		$175K Sell
20,121
-7,879
-28% -$47.1K 0.01% 220
2025
Q2 		$104K Buy
28,000
+2,805
+11% +$9.86K 0.01% 431
2025
Q1 		$75.4K Buy
25,195
+5,195
+26% +$24.5K 0.01% 386
2024
Q4 		$111K Buy
20,000
+10,000
+100% +$78.5K 0.01% 361
2024
Q3 		$108K Buy
+10,000
New +$166K 0.01% 282

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Proficio Capital Partners's FDMT Position: Q4 2025 in Review

Proficio Capital Partners sold out of 4D Molecular Therapeutics (FDMT) in Q4 2025, closing a stake of 20,121 shares — an estimated $175K sold.

Proficio Capital Partners first reported a position in FDMT in Q3 2024 and held it in 5 quarters. The position peaked at $175K in Q3 2025. 153 funds tracked by Wall St. Rank hold FDMT as of Q4 2025.

  • Proficio Capital Partners reported no remaining 4D Molecular Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Proficio Capital Partners sold 20,121 4D Molecular Therapeutics shares in Q4 2025, an estimated $175K.
  • Proficio Capital Partners first reported a position in 4D Molecular Therapeutics in Q3 2024 and held it in 5 quarters.
  • Proficio Capital Partners's 4D Molecular Therapeutics position peaked at $175K in Q3 2025.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2025.

Based on Proficio Capital Partners's 13F filing for Q4 2025, filed 12 Feb 2026.